We have studied the regional cerebral blood flow (rCBF) 
Introduction
The earliest descriptions of the use of L-dopa in Parkinson's disease already highlighted the question of drug-induced dyskinesia (Barbeau, 1969; Cotzias et al., 1969; Chase et al., 1973) . The variety of L-dopa-induced dyskinesias and the disability they induce have, since then, elicited continual attention from investigators interested in Parkinson's disease and movement disorders (Marsden et al., 1982; Agid et al., 1985; Nutt, 1990) . Peak-dose dyskinesia, occurring when Ldopa effects on parkinsonism are maximum, is the most common one. In spite of their common occurrence, the pathophysiology of peak-dose L-dopa-induced dyskinesia remains poorly understood (Marconi et al., 1994) . Experimental models of hyperkinetic movement disorders in the monkey suggest that an excessive stimulation of the cortical motor areas by an overactive basal gangliathalamocortical outflow may cause abnormal involuntary
© Oxford University Press 1998 a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi-and contralateral primary motor areas. These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopainduced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.
movements such as dyskinesia (Crossman, 1990; De Long, 1990) . However, there is, as yet, no definite published clinical observation to support the hypothesis that such a mechanism actually occurs in dyskinetic Parkinson's disease patients.
Brain mapping of active areas which play a part in voluntary movements, by measuring regional cerebral blood flow (rCBF) , has demonstrated that the activity of the supplementary motor area (SMA) is defective in akinetic Parkinson's disease patients Playford et al., 1992; Rascol et al., 1992 Rascol et al., , 1994 Rascol et al., , 1997 . This cortical hypoactivation is thought to reflect a decrease in the positive efferent feedback arising from the subcortical motor loop. If dyskinesia is related to an opposite phenomenon, it should then be possible to demonstrate it using a similar methodology.
The aims of the present study were thus to measure rCBF 
Material and methods Subjects
Thirty-eight male patients with Parkinson's disease were studied. They fulfilled the UK Parkinson's Disease Brain Bank criteria for the diagnosis of idiopathic Parkinson's disease (Gibb and Lees, 1988) . All patients had a clear positive motor response to L-dopa. All were studied in the 'on' (medication) condition, after their first morning dose, and none had tremor in the 'on' condition. Disability was recorded on the Hoehn and Yahr (1967) scale and the Unified Parkinson's Disease Rating Scale (UPDRS) (Fahn et al., 1987) immediately before the patients were scanned. These 38 Parkinson's disease patients were divided into two groups. The first group consisted of 23 Parkinson's disease patients who had no abnormal involuntary movements in the 'on' condition (the non-dyskinetic group), whereas the second group consisted of the other 15 Parkinson's disease patients who presented mild, but typical, peak-dose dyskinesia in the 'on' condition (the dyskinetic group). All dyskinetic Parkinson's disease patients had been screened in order to eliminate those with abnormal head movements which could have prevented rCBF data acquisition. The main clinical features of Parkinson's disease patients from both groups are summarized in Table 1 . These two groups of Parkinson's disease patients were compared with 14 normal volunteers (all men, mean age 50 Ϯ 3 years). All were neurologically normal. For both the control subjects and the patients with Parkinson's disease, handedness was determined informally. However, handedness was not considered in the analysis of results, because we had previously demonstrated, with the same technique, that this motor task induces mirror symmetrical rCBF changes when performed with the dominant or nondominant hand (Sabatini et al., 1993) . Informed consent was obtained from all patients and normal volunteers and the study was approved by the local ethical committee (Toulouse I).
Motor task
Two rCBF measurements were obtained in the morning of the same day, once the subject was fully in the 'on' condition, after his first L-dopa dose. There was a 60-min interval between each scan; one measurement was obtained during the execution of the motor task and the second in the resting state, the order of these two measurements being randomly allocated. Motor task and resting states were balanced for visual and auditory stimuli and were performed under conditions of sensory deprivation. Subjects were asked to keep their eyes closed.
The motor task has been described and used in previous protocols (Rascol et al., 1992 (Rascol et al., , 1994 (Rascol et al., , 1997 Sabatini et al., 1993) . It consisted of repeated sequential finger-to-thumb opposition movements in turn, lasting for the 4 min of the rCBF data acquisition. We measured the way in which each subject performed the motor task using video recordings of the hand movements. This enabled measurement of the frequency (number of finger-to-thumb oppositions each minute) and amplitude (0-3 scale) of the movements involved. Subjects had been pretrained to execute the motor task until they had shown that they were able to perform the movement with a stable amplitude and frequency. To make sure that normal subjects and patients with Parkinson's disease executed the motor task with a similar performance, they were all asked to achieve a moderate amplitude (2 on the three-point scale) with a mean frequency of~30/min. At the end of the study, the video recordings of all the subjects were analysed blindly to compare the mean amplitudes and frequencies of the three groups.
In every subject, the absence or presence of any involuntary abnormal movement occurring during the activation or in the resting state was assessed both visually, during the rCBF measurements, and retrospectively, on the video recordings.
rCBF measurement
The technique which we used in our laboratory to measure rCBF has been described previously (Rascol et al., 1992 (Rascol et al., , 1994 (Rascol et al., , 1997 Sabatini et al., 1993) . rCBF was measured using single photon emission tomography (SPECT) (Tomomatic 64, Medimatic, Copenhagen, Denmark) and intravenous injection of 133 Xe (2220 MBq) (Celsis et al., 1981) . The mean global flow was measured from data collected from three transverse slices simultaneously at 0, 4 and 8 cm above the canthomeatal plane. rCBF changes were studied in three regions of interest from slice 3: a medial anterior region of interest corresponding to the two SMAs (12 pixels) and two symmetrical and lateral regions of interest (16 pixels each) corresponding to the primary sensory motor areas contralateral and ipsilateral to the hand executing the motor task (contralateral and ipsilateral S 1 M 1 , respectively).
The rCBF data obtained in these three cortical motor regions of interest were normalized with a global factor calculated from the CBF of the three slices (global rCBF at rest/global rCBF during motor task); the rCBF value of each region of interest, collected during the motor task, was multiplied by this factor to eliminate non-specific rCBF changes. Localization of the regions of interest on the scans were carried out blind. The PaCO 2 was continuously recorded using cutaneous electrode and a PaCO 2 monitor (Kontron 634, Kontron, Basel, Switzerland). Systolic and diastolic blood pressure were measured at the time of each rCBF measurement.
Statistical analysis
The demographic variables of the three groups of subjects were compared using a univariate analysis of variance (ANOVA) or an unpaired Student's t test.
The rCBF values of the three regions of interest were compared between the resting condition and the motor activation condition using a paired Student's t test. The comparison across the three groups of subjects of the percentage changes in rCBF induced by the execution of the motor task in the three regions of interest was performed using a multivariate analysis of variance (MANOVA). A post hoc univariate analysis (Duncan test) was examined if significant F-values were found. Significance was accepted when P Ͻ 0.05. Results are expressed as mean Ϯ SEM.
Results
The normal subjects, and non-dyskinetic and dyskinetic Parkinson's disease patients executed the motor task with a similar rate and amplitude (Table 2) .
Normal subjects and non-dyskinetic Parkinson's disease patients exhibited no visible movements other than those of the hand executing the motor task for the activation paradigm. In contrast, all the dyskinetic Parkinson's disease patients exhibited mild peak-dose choreic dyskinesia when performing the motor task during the 4 min of data acquisition. Dyskinesia was widely distributed (face, ipsi-and/or contralateral limbs) in the majority of patients. The severity of these dyskinesias was ഛ2 on the UPDRS scale (part IV) and there was no head movement incompatible with data acquisition. In the resting state, almost no involuntary abnormal movement was observed, the dyskinetic patients remaining quiet and relaxed.
There were no differences in blood pressure or PaCO 2 between the three groups, or in the same group from one scan to the other. At rest, there were no significant differences between the three groups in rCBF in any of the regions of interest, although values were greater in the group of normal subjects. At rest, in each group, there was no difference in rCBF between the ipsilateral and contralateral S 1 M 1 . There was no significant difference between the three groups in the global normalization factor.
The execution of the motor task induced a significant increase in rCBF in the contralateral S 1 M 1 (P Ͻ 10 -3 ) and in the SMA (P Ͻ 0.05) of the normal subjects. In the nondyskinetic and dyskinetic groups of Parkinson's disease patients, rCBF increased during the session of motor activation in the SMA (P Ͻ 10 -3 ), in the contralateral S 1 M 1 (P Ͻ 10 -3 ) and the ipsilateral S 1 M 1 (P Ͻ 10 -2 ) ( Table 3) .
There was a significant interaction between groups and regions of interest when comparing percentage changes in rCBF (ANOVA, P ϭ 0.01); the percentage change in rCBF was significantly greater in the SMA, and the ipsi-and contralateral S 1 M 1 of the dyskinetic group compared with that in the other two groups (see Fig. 1 ).
Discussion
Because of the limits of the spatial resolution of our tomograph, we deliberately chose to study only a limited number of cortical regions of interest corresponding to the primary motor cortex and to the mesial motor cortex. These three areas were chosen because their activation is known to be differently affected when akinetic Parkinson's disease patients perform a motor task Rascol et al., 1992 Rascol et al., , 1994 . Our regions of interest may include parts of structures other than those specified; e.g. it is likely that our S 1 M 1 regions of interest also include the premotor areas. Also, other cortical and subcortical motor areas are involved in motor activity and may play an important role in the pathophysiology of L-dopa-induced dyskinesia. Keeping in mind such limitations, the present data show, however, that Fig. 1 Comparisons of percentage changes in rCBF (mean Ϯ SEM) induced by motor activation in the three cortical regions of interest of the three groups of subjects. The hemisphere ipsilateral to the hand movement is drawn on the right. There is a group and region of interest interaction (MANOVA, P Ͻ 0.05). **P Ͻ 0.01 for dyskinetic Parkinson's disease patients versus normal subjects and P Ͻ 0.01 and $ P Ͻ0.05 for dyskinetic Parkinson's disease (PD) patients versus non-dyskinetic ones (post hoc Duncan test). there is a significant overactivation of the supplementary and primary motor cortical areas in dyskinetic patients with Parkinson's disease. This result is compatible with the hypothesis that a hyperkinetic disorder, like peak-dose dyskinesia, is related to a disinhibition of thalamocortical projections. To our best knowledge, this is the first time that this has been demonstrated in human parkinsonian patients.
In the present study, we selected two separate groups of Parkinson's disease patients, according to the presence or absence, in the 'on' condition, of L-dopa-induced peak-dose dyskinesia. There were, however, several other differences between these two groups, specially regarding their L-dopa treatment; the dyskinetic group had a larger mean L-dopa daily dose and a longer mean duration of medication with Ldopa than the non-dyskinetic group. These data are not surprising since the emergence of dyskinesia may be related to the cumulative dose of L-dopa (Nutt, 1990) . It is also possible that these differences in medication with L-dopa reflect the fact that the underlying disease might have been more severe in the dyskinetic group than in the non-dyskinetic one, the disease severity being considered as another contributing factor in the genesis of dyskinesia (Horstink et al., 1990; Cedarbaum et al., 1991) . There are two possible ways to link these differences in medication with L-dopa with the excessive rCBF motor activation observed in the dyskinetic group: (i) the overactivation could simply be due to a direct vasodilatory effect of L-dopa on cerebral vessels; and (ii) the rCBF changes could indeed reflect increased synaptic and neuronal activity in the underlying corresponding cortical areas. It is well known that most dopaminergic agents induce a global cerebral vasodilation in Parkinson's disease patients (Leenders et al., 1985; Montastruc et al., 1987; Sabatini et al., 1991) . Thus, in the dyskinetic group, a larger daily dose of L-dopa may have amplified rCBF changes during the execution of the motor task. There are, however, several reasons which make this hypothesis unlikely. First, such a global and non-specific dopaminergic cerebral vasodilating effect should have been suppressed by the normalization procedure that we used to express rCBF data (see Materials and methods). Moreover, there was no difference in this global normalization factor between the three groups. Secondly, it has been demonstrated on several occasions that the cerebral peripheral vasodilation induced by dopamine agents disappears after a few weeks of treatment (Leenders et al., 1985; Sabatini et al., 1991) . In the present study, all the Parkinson's disease patients had been treated with L-dopa for several years. Thirdly, all scans were performed in both groups while the patients were fully in the 'on' condition (after their first morning dose of L-dopa, following 12 h overnight without the drug). This morning dose was not different between the groups (Table 1) . Fourthly, if L-dopa had significantly modified the activation data via a peripheral vascular effect in dyskinetic patients, it would also have done so in the non-dyskinetic patients compared with the normal subjects. This was not the case. Fifthly, we performed an a posteriori analysis of rCBF changes in a 'neutral' brain area corresponding to one single region of interest (20 pixel) including the bilateral medial occipital visual cortex on slice 2. In contrast with the three motor regions of interest, no significant difference in percentage change in rCBF was observed among the three groups of subjects (normal subjects, ϩ1 Ϯ 2%; non-dyskinetic Parkinson's disease patients, -3 Ϯ 1%; dyskinetic Parkinson's disease patients, ϩ2 Ϯ 3%). Therefore, we assume that the observed differences in activation of motor areas are not related to a non-specific general L-dopa effect. However, we cannot definitely rule out a possible regional effect of L-dopa on motor activation patterns.
We checked that, at the moment of the study, both dyskinetic and non-dyskinetic Parkinson's disease groups had a similar motor handicap, when tested in the 'on' condition, as demonstrated by the Hoehn and Yahr scale and the motor examination score of the UPDRS (Table 1) . We also checked that dyskinetic and non-dyskinetic patients, as well as normal controls, executed the motor task with similar movement rates and amplitudes (Table 2) . Therefore, we assume that the greater rCBF motor activation that we observed in the patients suffering from L-dopa-related peak-dose dyskinesia can only be explained by an abnormal increase in synaptic and neuronal activity in the corresponding cortical areas.
It could be suggested that part of the overactivation observed in the frontal association areas in dyskinetic Parkinson's disease patients was a result of these patients making additional efforts because they were trying to suppress or overcome the involuntary dyskinetic movements. They were asked not to do so, and to remain as relaxed as possible. However, we have no objective measure to eliminate such a possibility.
Our demonstration of SMA overactivation of the dyskinetic Parkinson's disease group is the exact opposite of the reported SMA hypoactivation in akinetic Parkinson's disease patients in the 'off' condition Rascol et al., 1992 Rascol et al., , 1994 . Although we could not measure rCBF changes in the basal ganglia with our technique, this result suggests, considering the experimental data obtained in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned monkey, that a disinhibition of the thalamocortical projections is leading to an overactivation of the mesial frontal cortex in dyskinetic Parkinson's disease patients (Crossman, 1990; De Long, 1990; Mitchell et al., 1990) . Few comparable results in humans have been published until now. The Bereitschaftspotential amplitude, which may reflect the SMA electrical activity, was reported to be abnormally large in patients suffering from another type of abnormal movement, namely tardive dyskinesia (Adler et al., 1989) . PET studies have also shown that the SMA is overactive in patients with idiopathic torsion dystonia or acquired hemidystonia (Ceballos-Baumann et al., 1995a, b) . Three studies have looked at the pattern of motor activation in Parkinson's disease patients under treatment Rascol et al., 1992 Rascol et al., , 1994 . Unfortunately, none has specially considered the problem of dyskinesia. Recently, however, Piccini et al. (1997) produced preliminary results in three Parkinson's disease patients with L-dopa-induced dyskinesia. These authors were able to correlate rCBF changes in the motor cortex with the severity of dyskinesia, suggesting, as we do, that pallidofrontal projections are overactive during dyskinetic movements in Parkinson's disease patients.
In the present study, we also observed, in the dyskinetic Parkinson's disease group, that both the ipsi-and the contralateral primary motor areas were overactivated compared with normal subjects and non-dyskinetic Parkinson's disease patients. The fact that the motor task was executed in a similar way by all three groups strongly suggests that this overactivation is related to the presence of dyskinesia. To go further and link dyskinetic movements with the activity of the primary motor cortex, we compared, a posteriori, the activation of the ipsilateral primary motor cortex (i.e. the one which was not predicted to be activated by the motor task) in the two subgroups of dyskinetic patients: those with (n ϭ 8) and those without (n ϭ 7) dyskinetic movements involving the hemibody opposite to the hand executing the motor task. The difference in rCBF activation was striking, being ϩ16 Ϯ 4% in the first subgroup and ϩ4 Ϯ 1% in the second one (P Ͻ 0.05, Mann-Whitney test). This result suggests, as anticipated, that the presence of dyskinetic movements on one side of the body was linked to the activation of the contralateral primary motor cortex. Samuel et al. (1997) recently reported that the lateral premotor cortex is overactive in Parkinson's disease patients performing a limb movement, suggesting that there is a switch from the use of striatomesial frontal to parietolateral premotor circuits in order to facilitate movements. As already stated, our S 1 M 1 region of interest probably includes at least part of the premotor cortex. However, we do not think that our results are related to this phenomenon because Samuel et al. (1997) studied their patients in the 'off' condition, while we studied ours in the 'on' condition, i.e. when overactivity of nonstriatomesial frontal motor pathways is unlikely to be present (Rascol et al., 1997) . Such an increased activation of the sensorimotor cortex in dyskinetic Parkinson's disease patients is similar to that reported in aquired hemidystonia (CeballosBaumann et al., 1995b) but differs from the impaired activation of sensorimotor cortex observed in idiopathic dystonia (Ceballos-Baumann et al., 1995a) . It can be suggested that the overactivity of the primary motor cortex in dyskinetic patients, as well as in patients with acquired dystonia, reflects the fact that there is a relatively focal basal ganglia dysfunction in these two conditions, whereas in idiopathic dystonia, both the basal ganglia and the motor cortex are affected by the pathology.
It is interesting to note that the rCBF activation of the SMA and ipsilateral primary motor cortex was larger in the non-dyskinetic Parkinson's disease patients than in the control group (see Fig. 1 ), although not significantly. These values were indeed intermediate between those from normal subjects and dyskinetic Parkinson's disease patients. It is tempting to suggest that, in the non-dyskinetic Parkinson's disease group, some kind of a presymptomatic rCBF overactivation was present, but was not sufficient to induce abnormal movements. This observation provides additional arguments to support the hypothesis that such a cortical overactivation is due to a motor thalamocortical disinhibition rather than to an additional volitional effort, aimed at suppressing involuntary dyskinetic movements.
Finally, the fact that the dopaminergic mesocortical pathway densely innervates motor, premotor and SMAs in primates (Berger et al., 1991) must be considered. It is not possible to exclude the hypothesis that a direct effect of the mesocortical dopamine pathways on cortical motor targets may also participate in the pathophysiology of dyskinesia, in parallel with the indirect effects exerted by the nigrostriatal pathway influencing the subcortical-cortical loops relaying through the basal ganglia.
In conclusion, the results of the present study suggest that peak-dose dyskinesia in patients with Parkinson's disease occurs while there is an overactivation of the supplementary and primary cortical motor areas. These results can be interpreted as an abnormal cortical excitation due to a defective inhibition of the thalamic nuclei relaying the putaminopallidal motor output. In view of the low resolution of the SPECT and the limited number of brain regions analysed, PET studies, using cameras with a better spatial definition are required to define the role of other cortical and subcortical motor centres, to understand the pathophysiology of L-dopa-induced dyskinesia better.
